These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15487959)

  • 1. The direct thrombin inhibitor melagatran/ximelagatran.
    Brighton TA
    Med J Aust; 2004 Oct; 181(8):432-7. PubMed ID: 15487959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
    Evans HC; Perry CM; Faulds D
    Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ximelagatran: direct thrombin inhibitor.
    Ho SJ; Brighton TA
    Vasc Health Risk Manag; 2006; 2(1):49-58. PubMed ID: 17319469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral direct thrombin inhibitors in clinical development.
    Gustafsson D
    J Intern Med; 2003 Oct; 254(4):322-34. PubMed ID: 12974871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ximelagatran--a promising new drug in thromboembolic disorders.
    Petersen P
    Curr Pharm Des; 2005; 11(4):527-38. PubMed ID: 15725069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ximelagatran.
    Choudhury A; Goyal D; Lip GY
    Drugs Today (Barc); 2006 Jan; 42(1):3-19. PubMed ID: 16511607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ximelagatran: a new oral anticoagulant.
    Hrebickova L; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(6):397-408. PubMed ID: 14633322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ximelagatran: an orally active direct thrombin inhibitor.
    Gulseth MP
    Am J Health Syst Pharm; 2005 Jul; 62(14):1451-67. PubMed ID: 15998925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review.
    Gustafsson D; Elg M
    Thromb Res; 2003 Jul; 109 Suppl 1():S9-15. PubMed ID: 12818629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
    Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Lassen MR; Mouret P; Rosencher N; Kälebo P; Panfilov S; Eskilson C; Andersson M; Freij A;
    J Thromb Haemost; 2003 Dec; 1(12):2490-6. PubMed ID: 14675083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
    Eriksson UG; Bredberg U; Gislén K; Johansson LC; Frison L; Ahnoff M; Gustafsson D
    Eur J Clin Pharmacol; 2003 May; 59(1):35-43. PubMed ID: 12743672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation.
    McCullough PA; Dorrell KA; Sandberg KR; Yerkey MW
    Rev Cardiovasc Med; 2004; 5(2):99-103. PubMed ID: 15184843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era..
    Mohapatra R; Tran M; Gore JM; Spencer FA
    Am Heart J; 2005 Jul; 150(1):19-26. PubMed ID: 16084146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.
    Sarich TC; Teng R; Peters GR; Wollbratt M; Homolka R; Svensson M; Eriksson UG
    Clin Pharmacokinet; 2003; 42(5):485-92. PubMed ID: 12739986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.
    Bredberg E; Andersson TB; Frison L; Thuresson A; Johansson S; Eriksson-Lepkowska M; Larsson M; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):765-77. PubMed ID: 12846597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation.
    Hellgren M; Johansson S; Eriksson UG; Wåhlander K
    BJOG; 2005 May; 112(5):579-83. PubMed ID: 15842280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.